MBCProject_3946_T5B_RNA
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.620
- FATTY_ACID_METABOLISM+0.390
- PANCREAS_BETA_CELLS+0.380
- PROTEIN_SECRETION+0.370
- BILE_ACID_METABOLISM+0.240
- PEROXISOME+0.240
- ADIPOGENESIS+0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
- ANDROGEN_RESPONSE+0.180
- XENOBIOTIC_METABOLISM+0.180
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- MYC_TARGETS_V2-0.440
- E2F_TARGETS-0.400
- INFLAMMATORY_RESPONSE-0.380
- TNFA_SIGNALING_VIA_NFKB-0.380
- ALLOGRAFT_REJECTION-0.360
- MYC_TARGETS_V1-0.320
- WNT_BETA_CATENIN_SIGNALING-0.310
- G2M_CHECKPOINT-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_3946_T5A_RNA | — | C | 0.954 |
| 2 | SRR8518189 | — | F | 0.871 |
| 3 | TCGA-78-7163-01A-12R-2066-07 | — | cohortA1 | 0.868 |
| 4 | SRR8613744 | — | F | 0.828 |
| 5 | TCGA-44-6776-01A-11R-1858-07 | — | cohortA2 | 0.827 |
| 6 | TCGA-B6-A0RO-01A-22R-A084-07 | — | C | 0.825 |
| 7 | SRR1101421 | GTEX | — | 0.825 |
| 8 | 20070161.TNBC | — | F | 0.823 |
| 9 | SRR8943024 | — | — | 0.820 |
| 10 | 84a15687-a977-43a1-b2b7-099ecdf21b2c | — | — | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.620 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.390 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.010 | Inavolisib | — uncovered |